Payment overview · 2025
General Payments
$410.37
23 reported records · 12 companies
Healthcare provider profile · identity verified
Anabel Lucanie, MD
Allopathic & Osteopathic Physicians|Internal Medicine · RAMSEY, NJ · NPI 1295736577
Verified facts
What the public records show
CMS Open Payments records show Anabel Lucanie, MD received $410.37 in general payments during 2025 across 23 reported records.
PFIZER INC. accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Paxlovid, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $80.91 | 19.7% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $71.03 | 17.3% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.05 | 12.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.31 | 11.5% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.00 | 9.3% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.86 | 4.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.72 | 4.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $18.27 | 4.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.00 | 4.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.34 | 4.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.93 | 3.9% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $13.95 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $410.37 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $71.03 | 4 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $71.03 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $61.94 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $61.94 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $61.94 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $47.31 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $38.00 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.49 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.49 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 17 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
27 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
68 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 498 | 164 |
| Amlodipine Besylate | Amlodipine Besylate | 472 | 160 |
| Levothyroxine Sodium | Levothyroxine Sodium | 457 | 137 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 292 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 260 | 83 |
| Simvastatin | Simvastatin | 176 | 56 |
| Famotidine | Famotidine | 165 | 67 |
| Lorazepam | Lorazepam | 163 | 60 |
| Losartan Potassium | Losartan Potassium | 156 | 53 |
| Lisinopril | Lisinopril | 149 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 146 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 48 |
| Alprazolam | Alprazolam | 125 | 57 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 122 | 35 |
| Irbesartan | Irbesartan | 112 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 38 |
| Omeprazole | Omeprazole | 109 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 35 |
| Prednisone | Prednisone | 102 | 75 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 93 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 21 |
| Eliquis | Apixaban | 68 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 22 |
| Cefuroxime | Cefuroxime Axetil | 66 | 43 |
| Metformin Hcl | Metformin Hcl | 64 | 21 |
| Gabapentin | Gabapentin | 63 | 19 |
| Synthroid | Levothyroxine Sodium | 63 | 17 |
| Torsemide | Torsemide | 63 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 25 |
| Benazepril Hcl | Benazepril Hcl | 59 | 18 |
| Ramipril | Ramipril | 56 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 56 | 18 |
| Allopurinol | Allopurinol | 55 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 48 |
| Alendronate Sodium | Alendronate Sodium | 52 | 14 |
| Methenamine Hippurate | Methenamine Hippurate | 52 | 16 |
| Montelukast Sodium | Montelukast Sodium | 49 | 17 |
| Celecoxib | Celecoxib | 48 | 19 |
| Metformin Hcl Er | Metformin Hcl | 48 | 18 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 47 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 16 |
| Meloxicam | Meloxicam | 45 | 16 |
| Atenolol | Atenolol | 44 | 14 |
| Bupropion Xl | Bupropion Hcl | 44 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 14 |
| Sertraline Hcl | Sertraline Hcl | 44 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 18 |
| Terazosin Hcl | Terazosin Hcl | 41 | 13 |
| Ezetimibe | Ezetimibe | 40 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 39 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 11 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 37 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | 13 |
| Azithromycin | Azithromycin | 34 | 30 |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Naproxen | Naproxen | 32 | 20 |
| Valsartan | Valsartan | 31 | 12 |
| Azelastine Hcl | Azelastine Hcl | 30 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 13 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Myrbetriq | Mirabegron | 27 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 23 | suppressed |
| Tadalafil | Tadalafil | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Livalo | Pitavastatin Calcium | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 18 | 18 |
| Diazepam | Diazepam | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | 13 |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 15 |
| Ozempic | Semaglutide | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Trimethoprim | Trimethoprim | 15 | suppressed |
| Edarbi | Azilsartan Medoxomil | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 11 |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Linzess | Linaclotide | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Diovan Hct | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Furosemide | Furosemide | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 12 | suppressed |
| Viberzi | Eluxadoline | 12 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $410.37 · 23 records | PFIZER INC. | ABRYSVO, AREXVY, CAPVAXIVE, COMIRNATY, EVENITY, FARXIGA, GARDASIL 9, NEFFY, NURTEC ODT, OTEZLA, PAXLOVID, PREVNAR 20, REPATHA, TRELEGY ELLIPTA, TZIELD, VOQUEZNA, Veozah, WATCHMAN Access System, Wegovy, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Paxlovid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error